Drug Abuse Withdrawal Supplement Marketers Warned, Claims And Sales Continue
This article was originally published in The Rose Sheet
Executive Summary
FDA and FTC send joint warning letters to 11 US firms about 12 products marketed as unapproved drugs with claims about aiding in the treatment of opioid addiction and withdrawal. FDA also thanks CSPI for suggesting the agencies investigate a scourge of fraudulent drug-abuse withdrawal claims.
You may also be interested in...
Opioid Abuse Treatment Claims Prompt FDA Warnings To Two Kratom Marketers
As in previous warnings to kratom supplement marketers linked to opioid addiction treatment claims, FDA tells Cali Botanicals and Kratom NC that HHS in 2017 found opioid abuse was nationwide public health emergency and FDA is targeting products that without approval claim to diagnose, mitigate, prevent, treat or cure opioid addiction. Contract manufacturer Somlabs' GMP problems also were identified in FDA's latest warning letters.
FDA Urged To Crack Down On Supplements For Nicotine Addiction
The Center for Science in the Public Interest urges the US Food and Drug Administration to seize products from marketers of 15 dietary supplements that claim to treat nicotine addiction. In an April 24 letter, the advocacy group says none of the marketers could present evidence in support of claims promising quick relief from addiction and/or results comparable to FDA-approved Rx and OTC drug products.
OTC Tramadol Sales By 21 Online Pharmacies Found In US FDA Sweep
FDA warns four online pharmacies associated with websites selling opioid products without prescriptions and advises more crack-downs are on horizon. Products identified in the warnings, formulated with tramadol, and other drugs sold on the websites are misbranded and unapproved new drugs.